News & Updates
Showing Multidisciplinary articles
Showing
Retatrutide poised to be the next weight-loss option for T2D with obesity
In the phase III TRIUMP-2 trial, retatrutide improves glycaemic control and reduces body weight in adults with type 2 diabetes (T2D) who are overweight or have obesity, potentially expanding weight-loss options for this population.
ARCADIA LTE supports long-term efficacy, safety of nemolizumab for AD
The open-label long-term extension (LTE) of the ARCADIA trial demonstrates the safety and efficacy of nemolizumab for up to 152 weeks in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
Toripalimab consolidation after cCRT signals PFS and OS benefits in Chinese patients with LS-SCLC
A randomized, multicentre, phase II trial reports signals of improved progression-free survival (PFS) and overall survival (OS) with toripalimab consolidation after concurrent chemoradiotherapy (cCRT) in Chinese patients with limited-stage (LS) small-cell lung cancer (SCLC).
Sacituzumab tirumotecan still effective in pretreated metastastic TNBC despite dose modification
A detailed safety analysis of the phase III, multicenter, open-label, randomized, controlled OptiTROP-Breast01 trial suggests that sacituzumab tirumotecan (sac-TMT) has a manageable safety profile and that adverse events (AEs) can be effectively managed through dose modification and appropriate supportive care without compromising its efficacy in previously treated metastatic triple-negative breast cancer (mTNBC).
